丹槐银屑浓缩丸对豚鼠银屑病样模型组织VEGF、VEGFR含量的影响
|
摘要
目的:通过丹槐银屑浓缩丸对豚鼠银屑病样模型耳部组织血管内皮生长因子( vascular endothelial growth factor , VEGF)及其受体( vascular endothelial growth factor receptor,VEGFR)水平影响的实验研究,探讨丹槐银屑浓缩丸治疗银屑病的作用机制。
方法:将70只豚鼠随机分成7组,每组10只,即:空白组、模型组、西药对照组(氨甲喋呤组)、成药对照组(复方青黛胶囊组)、以及丹槐银屑浓缩丸低剂量组、中剂量组、高剂量组。用5%普萘洛尔乳剂外涂豚鼠耳背制备银屑病样病理改变模型。采用双抗体夹心酶联免疫法测定组织VEGF,VEGFR含量,观察其与皮损表现的关系。所得数据用SPSS13.0软件进行统计分析,计算均数、标准差,计量资料采用T检验,方差分析。
结果:丹槐银屑浓缩丸高、中、低剂量组VEGF水平下降不明显( P>0.05),VEGFR水平出现不同程度下降,特别是中剂量组与其它组差异显著(P<0.01或P<0.05)。
结论:丹槐银屑浓缩丸可使组织VEGFR水平显著降低,进而抑制血管内皮细胞增生,改善豚鼠银屑病样模型的皮损变化。
Objective: To investigate the effect of“Danhuai Yinxie Concentrated Pill”(DYCP) on the level of vascular endothelial growth factor(VEGF)and its receptor VEGFR in psoriasis-like guinea pigs' cutaneous lesions, so as to explore the mechanism of DYCP’s treatment for psoriasis.
Methods: 70 guinea pigs were randomly divided into 7 groups,10 in each group , namely:blank group, model group,western medicine group ( control group),chinese patent medicine group(control group), DYCP high, medium and low dose group(treatment group).The guinea pigs were made into models of psoriasis by external application of 5%propranolol cream at skin of ears. The contents of VEGF and VEGFR in cutaneous lesions were detected by ELISA, then study the relation between the contents of above detection and the manifestation of cutaneous lesions. The data were analyzed with SPSS13.0 software to calculate the mean, standard deviation. Measurement data using T test, analysis of variance.
Results: DYCP high, medium and low dose group showed a higher level,having no statistical difference with all the other groups(P>0.05). The level of VEGFR was declined to different degrees,especially for the medium dose group(P<0.01 or P<0.05 ).
Conclusion:“Danhuai Yinxie Concentrated Pill”could significantly reduce the level of VEGFR in cutaneous lesions, and then inhibit the proliferation of endothelial cells and improve cutaneous lesions of psoriasis-like guinea pigs.
方法:将70只豚鼠随机分成7组,每组10只,即:空白组、模型组、西药对照组(氨甲喋呤组)、成药对照组(复方青黛胶囊组)、以及丹槐银屑浓缩丸低剂量组、中剂量组、高剂量组。用5%普萘洛尔乳剂外涂豚鼠耳背制备银屑病样病理改变模型。采用双抗体夹心酶联免疫法测定组织VEGF,VEGFR含量,观察其与皮损表现的关系。所得数据用SPSS13.0软件进行统计分析,计算均数、标准差,计量资料采用T检验,方差分析。
结果:丹槐银屑浓缩丸高、中、低剂量组VEGF水平下降不明显( P>0.05),VEGFR水平出现不同程度下降,特别是中剂量组与其它组差异显著(P<0.01或P<0.05)。
结论:丹槐银屑浓缩丸可使组织VEGFR水平显著降低,进而抑制血管内皮细胞增生,改善豚鼠银屑病样模型的皮损变化。
Objective: To investigate the effect of“Danhuai Yinxie Concentrated Pill”(DYCP) on the level of vascular endothelial growth factor(VEGF)and its receptor VEGFR in psoriasis-like guinea pigs' cutaneous lesions, so as to explore the mechanism of DYCP’s treatment for psoriasis.
Methods: 70 guinea pigs were randomly divided into 7 groups,10 in each group , namely:blank group, model group,western medicine group ( control group),chinese patent medicine group(control group), DYCP high, medium and low dose group(treatment group).The guinea pigs were made into models of psoriasis by external application of 5%propranolol cream at skin of ears. The contents of VEGF and VEGFR in cutaneous lesions were detected by ELISA, then study the relation between the contents of above detection and the manifestation of cutaneous lesions. The data were analyzed with SPSS13.0 software to calculate the mean, standard deviation. Measurement data using T test, analysis of variance.
Results: DYCP high, medium and low dose group showed a higher level,having no statistical difference with all the other groups(P>0.05). The level of VEGFR was declined to different degrees,especially for the medium dose group(P<0.01 or P<0.05 ).
Conclusion:“Danhuai Yinxie Concentrated Pill”could significantly reduce the level of VEGFR in cutaneous lesions, and then inhibit the proliferation of endothelial cells and improve cutaneous lesions of psoriasis-like guinea pigs.
引文
[1]邵长庚.我国银屑病的流行和防治现状[J].中华皮肤科杂志,1996,29(2):75.
[2]唐翠兰,曹丽雅.银屑病患者的家庭养护[M].北京:科学技术文献出版社,2008.10-16.
[3]王学军,贾丽梅.丹槐银屑浓缩丸治疗寻常型银屑病264例临床观察[J].中国中医药科技,2008,15(6):474-475.
[4]Gaylarde PM,etal.Psoriasiform changes in guinea pig skin from propranolol.[J] Clinical and Experimental Dermatology.1978,3:157-160.
[5]Baker BS,Brent L,Valdimarsson H,et al. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?[J]. Br J Dermatol,1992, 126(2):105-110.
[6]张锡宝,罗权,吴志华,等.血管内皮生长因子及其受体在银屑病发病中的作用及意义[J].中华皮肤科杂志,2005,38(3):140-142.
[7]冯晓刚,耿春霞,吴明明.银屑病中医病因病机文献研究. [J]现代中西医结合杂志. 2009 18 (8):932
[8]李元文,张丰川.专科专病名医临证经验丛书皮肤病. [J]皮肤病. 2002:270-340.
[9]金起凤.消银解毒汤治疗银屑病58例疗效观察.[J]辽宁中医杂志.1983,(6):29-30
[10]周鸣岐.辨证分型治疗银屑病802例.[J]中医杂志.1989,30(5):42
[11]张志礼.皮肤病临床经验.[M]北京:中国医药科技出版社.2001,115.
[12]顾伯华.外科经验集.[M]上海:上海人民出版社.1977,252.
[13]丁履伸,赵绚德.银屑病的中医治疗.[J]山东中医学院学报.1980,4(4):47-49.
[14]徐国强.银屑病中医证治浅析.[J]世界中医药.2010,5(1):56-57
[15]王芳.运用清热凉血法治疗血热型进行期寻常型银屑病46例的临临床观察.[J]北京中医.2005,24(5):301-302.
[16]刘靖,查旭山.凉血消银汤治疗进行习期寻常型银屑病(血热证)32例疗效观察.[J]新中医.2006,38(8):28-29.
[17]熊波.从瘀证论治稳定期银屑病50例.[J]湖北中医杂志.2004,26(3):44.
[18]周淑维.庄国康教授治疗银屑病经验.[J]中国中西医结合皮肤性病学杂志.2004,3(1):37.
[19]陈丽红.消银汤治疗寻常型银屑病56例.[J]福建中医药.2004,35(2):26.
[20]郭奕妤.采用净屑饮治疗进行期寻常型银屑病30例.[J]广西中医药.2006,29(4): 25-26.
[21]贾庆梅.凉血活血消银汤治疗寻常型银屑病40例.[J]天津中医药.2007,24(1):54.
[22]赵林玉,车永强.穴位埋线治疗银屑病. [J]中华皮肤科杂志.1994,27(6):376.
[23]聂巧峰.四联法在银屑病治疗中的运用. [J]皮肤病与性病.2006,28(2):26-27.
[24]李福伦等,芩珠凉血合剂对豚鼠银屑病模型血管内皮生长因子及其受体表达的影响.[J]上海中医药大学学报.2008,22(6)43-46.
[25]金力,陈凯. CD34在寻常型银屑病中医辨证分型皮损中的表达. [J]中国皮肤性病学杂志.2006,20(5):273-275.
[26]范斌,李斌.凉血和活血中药对银屑病患者不同时期细胞因子的影响. [J]上海中医药杂志.2006,40(10):34-35.
[27]李斌,王婕.中医"血分论治"对寻常型银屑病患者外周血单个核细胞IFN-γ、IL-4表达影响的实验研究. [J]上海中医药杂志.2007,41(11):5-6.
[28]王禾.凉血活血胶囊治疗血热型银屑病的临床观察及外周血淋巴细胞亚群检测. [J]中国皮肤性病学杂志.2004,18(3):176.
[29]徐丽敏.血热型/血燥型银屑病患者外周血T淋巴细胞亚群变化. [J]中华皮肤科杂志.2006,39(10):600-601.
[30]张学军.皮肤性病学.[M]第7版.人民卫生出版社2008:141-144.
[31]郑敏.银屑病的发病机制和治疗的最新进展.2009全国中西医结合皮肤性病学术会议论文汇编.7-8
[32]魏娟.银屑病的发病机制与临床诊断进展. [J]黑龙江医学.2005,29(5):344-346.
[33]王永炎,王沛.今日中医外科.[M]北京:人民卫生出版社.2000.376.
[34]刘涛峰,张学军,杨森等.银屑病遗传流行病学初步分析.[J]安徽医科大学学报,1998,33(5):354-355.
[35]李敬,徐丽敏,毛舒和.银屑病易感基因位点PSORS1的研究进展[J]中国中西医结合皮肤性病学杂志.2004,3(4):250-253.
[36] Mallon E, BunceM, Savoie H, et al. HLA-Candgullate psoriadis. [J].Br J Dernatol,2000,143: 1177-1182.
[37] O Brien KP,Holm S J,Nilsson S,et al.The HCR gene on 6p21 is unliely to be a psoriasis susceptility gene. [J].JIn-Vest Dermatol,2001,116:750-754.
[38]何平平,杨森,王再兴等.染色体4q存在中国汉族人的银屑病易感基因. [J]中华皮肤科杂志.2003,36 (3):121-123.
[39]郝飞,叶庆伯,阎衡等.银屑病患者外周血单一核细胞CTLA4表达及基因多态性分析. [J]中华皮肤科杂志.2003,36(3):124-126.
[40]朱可建,商惠英,劳力民.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达. [J]中华皮肤科杂志.2003,36(3):142-144.
[41]周武庆,宁双飞,贾卫等.银屑病患者血清中可溶性血小板T细胞活化抗原1的检测. [J]中华皮肤科杂志.2003,36(3):159-160.
[42]王飞,Griffiths CEM,Kirby B等.自然杀伤细胞和T淋巴细胞在银屑病发病中作用的研究. [J]临床皮肤科杂志,2002,31(8):489-490.
[43]周海燕,郑家润.中性粒细胞在诱导银屑病急性炎症中的作用:中性粒细胞相关的炎症增强环路. [J]国外医学皮肤性病学分册.2001,27(3):170-173
[44]孙军红,方跃明,郑茂荣.银屑病与中性粒细胞趋化因子. [J]国外医学皮肤性病学分册.2000,26(5):271-273.
[45]余传霖,熊思东.分子免疫学. [M]上海:复旦大学出版社,2001.1235-1253.
[46] Bryan PP, Fred GW, Mark AG. Pathophysiology and treatment of psoriasis. [J]. AM J Heaith2Syst Pham, 2000.57:645.
[47] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokine rantes expression. [J].Biochem J,2000, 274(3):689-696.
[48] Wezler C, Kampfer H ,P feilschifter J, et al. Keratinocyte-derived chemotactic cytokines: expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo. [J].Biochem Biophys Res Commum,2000,274(3):689-696.
[49] Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. [J] J Invest Dermatol,1998, 111(1):1.
[50] Lawrence DA. Transforming growth factor-beta; a general reviews. [J] Eur Cytoki- ne Newt,1996, 7:363-374.
[51] Fierlbeck G, Rasser G, Muller C. Psoriasis induced at the injection site of recmbenant interferon gamma.[J] Arcb Dermatol Res 1990, 126:351-355.
[52] Hancock GE, Kaplan G, Cohn ZA. Kerati-nocyte growth regulation by theproducts of immune cells.[J] J Exp Med 1988, 168:1395-1402.
[53] Delaporte E,Bieber T,Viac J,etto-kines al.Cytokines epidermique et inflammation cutanee.[J] Ann Dermatol Venereol 1994, 121:836-843
[54] Lee RE, Gaspare AA, Lotze MT, et al. In-terleukin2 and psoriasis.[J] Arcb Dematol 1988, 124:1811-1815.
[55] Psquer P, Pierard GE. Iterliukin-6 and thskin.[J] Int Arch Allergy Immunol 1996, 109:308-317.
[56] Gilletzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNAin psoriasis amodel for neutro-phil migraton and accumulation in vivo. [J] Invest Dermatol 1996, 107:778-782.
[57] Leng X, Elias JA.Interleukin-11 inhibits macrophage interleukin-12 production. [J] Immunol 1997;159:2161-2168.
[58]黄建国,向吉夫,印道春等. 5-羟色胺在银屑病患者皮损中的表达. [J]中国麻风皮肤病杂志.2003,19(2):119-121.
[59]柳朋生.神经系统、免疫与皮肤的关系. [J]国外医学皮肤性病学分册.1999,25 (1):36-38.
[60]杜桂芹,常曼丽,王秀云.银屑病患者检测血小板指数及血流变的临床意义. [J]中国微循环,2004,8(3):180-181.
[61]王香兰,张秉正,王俊民等.银屑病中医分型的血流变学及超微结构相关性研究. [J]中国皮肤性病学杂志.2001,15(3):146-148.
[62]夏凯明,葛正义.银屑病患者的甲襞微循环及血液流变学改变.[J]浙江中西医结合杂志. 1999,9(4):259-260.
[63]孙宏伟,杜华,杨桂兰.银屑病病因与发病机制的研究进展[J].中国麻风皮肤病杂志.2008,24(1):50-52.
[64]兰长贵,吴良章,林新渝.泌乳素与免疫和自身免疫性疾病. [J].国外医学-皮肤性病学分册,1999,25:77-80.
[65]徐娟,贾随旺,钟绮丽等.银屑病皮损细胞凋亡的研究. [J]岭南皮肤性病科杂志.2004,11(2):91-93.
[66] Farber EM, Nickoloff BJ, Recht B, et al. Stress,symmetry,and psoriasis: possible role of neuropeptides. [J].J Am Acad Dermatol,1986,14:305-311.
[67]Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrithione. [J].Am J Dermatopathol,2000,22(3):272-276.
[68] Crutchfield CE 3rd,Lewis EJ,Zelickson BD.The highly effective use of topical zinc pyrithione in the treatment of psoriasis:a case report. [J].Dermatol Online J, 1997,3(1):3.
[69]韩凌,方栩,黄琼,等.吡硫翁锌气雾剂治疗寻常性银屑病的多中心、随机、开放试验. [J]中华皮肤科杂志,2008,41(7):478-479.
[70] Gup ta AK, Cherman AM. Efalizumab in the treatment of psoriasis. [J] J CutanMed Surg, 2006, 10 (2):57-68.
[71] Heiberg MS, Kaufmann C, Rdevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational multicentre study. [J]. Ann Rheum Dis, 2007,66 (8):1038-1042.
[72] Bandow GD, Koo JY. Narrow-band ultraviolet B radiation: a review of the current literature. [J]. Int J Dermatol, 2004, 43 (8):555-561.
[73]贺红霞,白莉.窄谱中波紫外线治疗寻常性银屑病的疗效观察. [J]中华皮肤科杂志, 2008, 41(3):194-195.
[74] Buske-Kirschbaum A, Kern S, Ebrecht M, et al. A ltered distribution of leukocyte subsets and cytokine p roduction in response to acute psycho social stress in patients with psoriasis vulgaris. [J].Brain Behav Immun, 2007, 21 (1) : 92-99.
[75]杨雪琴,李铀,杨光,等.生物反馈放松训练改善银屑病患者自主神经功能的研究. [J]中华皮肤科杂志,1999, 32 (2):132.
[76]邵长庚,杨雪琴,彭永年.银屑病防治研究及合理治疗.[M]北京:中国协和医科大学出版社,2006, 248-250.
[77]杨雪琴.银屑病的整体治疗研究. [J]解放军医学杂志.2009,3.34(3):246.
[78]黄畋,张淑芝,孙令.心得安涂药造成豚鼠耳部银屑病样病理变化[J].中华皮肤科杂志,1991,24(2):96-97.
[79]高学敏.中药学[M].北京:中国中医药出版社,2003.172.
[80]高学敏.中药学[M].北京:中国中医药出版社,2003.116.
[81]高学敏.中药学[M].北京:中国中医药出版社,2003.124.
[82]高学敏.中药学[M].北京:中国中医药出版社,2003.110.
[83]江苏新医学院.中药大词典[M].上海:上海人民出版社,1977.2434.
[84] Kalashnikova N A,Gerashchenko G I.Antiphlogistic activity of several flavonoids [J].Aktual Vopr Farm,1974(2):352.
[85]高学敏.中药学[M].北京:中国中医药出版社,2003.167.
[86]吴焕.活血化瘀药的活性成分和药理研究进展(续).中草药通讯,1979, (10):51.
[87]高学敏.中药学[M].北京:中国中医药出版社,2003.377.
[88]高学敏.中药学[M].北京:中国中医药出版社,2003.385.
[89]高学敏.中药学[M].北京:中国中医药出版社,2003.343.
[90]高学敏.中药学[M].北京:中国中医药出版社,2003.248.
[2]唐翠兰,曹丽雅.银屑病患者的家庭养护[M].北京:科学技术文献出版社,2008.10-16.
[3]王学军,贾丽梅.丹槐银屑浓缩丸治疗寻常型银屑病264例临床观察[J].中国中医药科技,2008,15(6):474-475.
[4]Gaylarde PM,etal.Psoriasiform changes in guinea pig skin from propranolol.[J] Clinical and Experimental Dermatology.1978,3:157-160.
[5]Baker BS,Brent L,Valdimarsson H,et al. Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?[J]. Br J Dermatol,1992, 126(2):105-110.
[6]张锡宝,罗权,吴志华,等.血管内皮生长因子及其受体在银屑病发病中的作用及意义[J].中华皮肤科杂志,2005,38(3):140-142.
[7]冯晓刚,耿春霞,吴明明.银屑病中医病因病机文献研究. [J]现代中西医结合杂志. 2009 18 (8):932
[8]李元文,张丰川.专科专病名医临证经验丛书皮肤病. [J]皮肤病. 2002:270-340.
[9]金起凤.消银解毒汤治疗银屑病58例疗效观察.[J]辽宁中医杂志.1983,(6):29-30
[10]周鸣岐.辨证分型治疗银屑病802例.[J]中医杂志.1989,30(5):42
[11]张志礼.皮肤病临床经验.[M]北京:中国医药科技出版社.2001,115.
[12]顾伯华.外科经验集.[M]上海:上海人民出版社.1977,252.
[13]丁履伸,赵绚德.银屑病的中医治疗.[J]山东中医学院学报.1980,4(4):47-49.
[14]徐国强.银屑病中医证治浅析.[J]世界中医药.2010,5(1):56-57
[15]王芳.运用清热凉血法治疗血热型进行期寻常型银屑病46例的临临床观察.[J]北京中医.2005,24(5):301-302.
[16]刘靖,查旭山.凉血消银汤治疗进行习期寻常型银屑病(血热证)32例疗效观察.[J]新中医.2006,38(8):28-29.
[17]熊波.从瘀证论治稳定期银屑病50例.[J]湖北中医杂志.2004,26(3):44.
[18]周淑维.庄国康教授治疗银屑病经验.[J]中国中西医结合皮肤性病学杂志.2004,3(1):37.
[19]陈丽红.消银汤治疗寻常型银屑病56例.[J]福建中医药.2004,35(2):26.
[20]郭奕妤.采用净屑饮治疗进行期寻常型银屑病30例.[J]广西中医药.2006,29(4): 25-26.
[21]贾庆梅.凉血活血消银汤治疗寻常型银屑病40例.[J]天津中医药.2007,24(1):54.
[22]赵林玉,车永强.穴位埋线治疗银屑病. [J]中华皮肤科杂志.1994,27(6):376.
[23]聂巧峰.四联法在银屑病治疗中的运用. [J]皮肤病与性病.2006,28(2):26-27.
[24]李福伦等,芩珠凉血合剂对豚鼠银屑病模型血管内皮生长因子及其受体表达的影响.[J]上海中医药大学学报.2008,22(6)43-46.
[25]金力,陈凯. CD34在寻常型银屑病中医辨证分型皮损中的表达. [J]中国皮肤性病学杂志.2006,20(5):273-275.
[26]范斌,李斌.凉血和活血中药对银屑病患者不同时期细胞因子的影响. [J]上海中医药杂志.2006,40(10):34-35.
[27]李斌,王婕.中医"血分论治"对寻常型银屑病患者外周血单个核细胞IFN-γ、IL-4表达影响的实验研究. [J]上海中医药杂志.2007,41(11):5-6.
[28]王禾.凉血活血胶囊治疗血热型银屑病的临床观察及外周血淋巴细胞亚群检测. [J]中国皮肤性病学杂志.2004,18(3):176.
[29]徐丽敏.血热型/血燥型银屑病患者外周血T淋巴细胞亚群变化. [J]中华皮肤科杂志.2006,39(10):600-601.
[30]张学军.皮肤性病学.[M]第7版.人民卫生出版社2008:141-144.
[31]郑敏.银屑病的发病机制和治疗的最新进展.2009全国中西医结合皮肤性病学术会议论文汇编.7-8
[32]魏娟.银屑病的发病机制与临床诊断进展. [J]黑龙江医学.2005,29(5):344-346.
[33]王永炎,王沛.今日中医外科.[M]北京:人民卫生出版社.2000.376.
[34]刘涛峰,张学军,杨森等.银屑病遗传流行病学初步分析.[J]安徽医科大学学报,1998,33(5):354-355.
[35]李敬,徐丽敏,毛舒和.银屑病易感基因位点PSORS1的研究进展[J]中国中西医结合皮肤性病学杂志.2004,3(4):250-253.
[36] Mallon E, BunceM, Savoie H, et al. HLA-Candgullate psoriadis. [J].Br J Dernatol,2000,143: 1177-1182.
[37] O Brien KP,Holm S J,Nilsson S,et al.The HCR gene on 6p21 is unliely to be a psoriasis susceptility gene. [J].JIn-Vest Dermatol,2001,116:750-754.
[38]何平平,杨森,王再兴等.染色体4q存在中国汉族人的银屑病易感基因. [J]中华皮肤科杂志.2003,36 (3):121-123.
[39]郝飞,叶庆伯,阎衡等.银屑病患者外周血单一核细胞CTLA4表达及基因多态性分析. [J]中华皮肤科杂志.2003,36(3):124-126.
[40]朱可建,商惠英,劳力民.寻常性银屑病患者外周血T淋巴细胞CD25和CD69的表达. [J]中华皮肤科杂志.2003,36(3):142-144.
[41]周武庆,宁双飞,贾卫等.银屑病患者血清中可溶性血小板T细胞活化抗原1的检测. [J]中华皮肤科杂志.2003,36(3):159-160.
[42]王飞,Griffiths CEM,Kirby B等.自然杀伤细胞和T淋巴细胞在银屑病发病中作用的研究. [J]临床皮肤科杂志,2002,31(8):489-490.
[43]周海燕,郑家润.中性粒细胞在诱导银屑病急性炎症中的作用:中性粒细胞相关的炎症增强环路. [J]国外医学皮肤性病学分册.2001,27(3):170-173
[44]孙军红,方跃明,郑茂荣.银屑病与中性粒细胞趋化因子. [J]国外医学皮肤性病学分册.2000,26(5):271-273.
[45]余传霖,熊思东.分子免疫学. [M]上海:复旦大学出版社,2001.1235-1253.
[46] Bryan PP, Fred GW, Mark AG. Pathophysiology and treatment of psoriasis. [J]. AM J Heaith2Syst Pham, 2000.57:645.
[47] Fank S, Kanpfer H, Wetzler C, et al. Large induction of the chemotactic cytokine rantes expression. [J].Biochem J,2000, 274(3):689-696.
[48] Wezler C, Kampfer H ,P feilschifter J, et al. Keratinocyte-derived chemotactic cytokines: expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo. [J].Biochem Biophys Res Commum,2000,274(3):689-696.
[49] Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. [J] J Invest Dermatol,1998, 111(1):1.
[50] Lawrence DA. Transforming growth factor-beta; a general reviews. [J] Eur Cytoki- ne Newt,1996, 7:363-374.
[51] Fierlbeck G, Rasser G, Muller C. Psoriasis induced at the injection site of recmbenant interferon gamma.[J] Arcb Dermatol Res 1990, 126:351-355.
[52] Hancock GE, Kaplan G, Cohn ZA. Kerati-nocyte growth regulation by theproducts of immune cells.[J] J Exp Med 1988, 168:1395-1402.
[53] Delaporte E,Bieber T,Viac J,etto-kines al.Cytokines epidermique et inflammation cutanee.[J] Ann Dermatol Venereol 1994, 121:836-843
[54] Lee RE, Gaspare AA, Lotze MT, et al. In-terleukin2 and psoriasis.[J] Arcb Dematol 1988, 124:1811-1815.
[55] Psquer P, Pierard GE. Iterliukin-6 and thskin.[J] Int Arch Allergy Immunol 1996, 109:308-317.
[56] Gilletzer R, Ritter U, Spandau U, et al. Differential expression of GRO-alpha and IL-8 mRNAin psoriasis amodel for neutro-phil migraton and accumulation in vivo. [J] Invest Dermatol 1996, 107:778-782.
[57] Leng X, Elias JA.Interleukin-11 inhibits macrophage interleukin-12 production. [J] Immunol 1997;159:2161-2168.
[58]黄建国,向吉夫,印道春等. 5-羟色胺在银屑病患者皮损中的表达. [J]中国麻风皮肤病杂志.2003,19(2):119-121.
[59]柳朋生.神经系统、免疫与皮肤的关系. [J]国外医学皮肤性病学分册.1999,25 (1):36-38.
[60]杜桂芹,常曼丽,王秀云.银屑病患者检测血小板指数及血流变的临床意义. [J]中国微循环,2004,8(3):180-181.
[61]王香兰,张秉正,王俊民等.银屑病中医分型的血流变学及超微结构相关性研究. [J]中国皮肤性病学杂志.2001,15(3):146-148.
[62]夏凯明,葛正义.银屑病患者的甲襞微循环及血液流变学改变.[J]浙江中西医结合杂志. 1999,9(4):259-260.
[63]孙宏伟,杜华,杨桂兰.银屑病病因与发病机制的研究进展[J].中国麻风皮肤病杂志.2008,24(1):50-52.
[64]兰长贵,吴良章,林新渝.泌乳素与免疫和自身免疫性疾病. [J].国外医学-皮肤性病学分册,1999,25:77-80.
[65]徐娟,贾随旺,钟绮丽等.银屑病皮损细胞凋亡的研究. [J]岭南皮肤性病科杂志.2004,11(2):91-93.
[66] Farber EM, Nickoloff BJ, Recht B, et al. Stress,symmetry,and psoriasis: possible role of neuropeptides. [J].J Am Acad Dermatol,1986,14:305-311.
[67]Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrithione. [J].Am J Dermatopathol,2000,22(3):272-276.
[68] Crutchfield CE 3rd,Lewis EJ,Zelickson BD.The highly effective use of topical zinc pyrithione in the treatment of psoriasis:a case report. [J].Dermatol Online J, 1997,3(1):3.
[69]韩凌,方栩,黄琼,等.吡硫翁锌气雾剂治疗寻常性银屑病的多中心、随机、开放试验. [J]中华皮肤科杂志,2008,41(7):478-479.
[70] Gup ta AK, Cherman AM. Efalizumab in the treatment of psoriasis. [J] J CutanMed Surg, 2006, 10 (2):57-68.
[71] Heiberg MS, Kaufmann C, Rdevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational multicentre study. [J]. Ann Rheum Dis, 2007,66 (8):1038-1042.
[72] Bandow GD, Koo JY. Narrow-band ultraviolet B radiation: a review of the current literature. [J]. Int J Dermatol, 2004, 43 (8):555-561.
[73]贺红霞,白莉.窄谱中波紫外线治疗寻常性银屑病的疗效观察. [J]中华皮肤科杂志, 2008, 41(3):194-195.
[74] Buske-Kirschbaum A, Kern S, Ebrecht M, et al. A ltered distribution of leukocyte subsets and cytokine p roduction in response to acute psycho social stress in patients with psoriasis vulgaris. [J].Brain Behav Immun, 2007, 21 (1) : 92-99.
[75]杨雪琴,李铀,杨光,等.生物反馈放松训练改善银屑病患者自主神经功能的研究. [J]中华皮肤科杂志,1999, 32 (2):132.
[76]邵长庚,杨雪琴,彭永年.银屑病防治研究及合理治疗.[M]北京:中国协和医科大学出版社,2006, 248-250.
[77]杨雪琴.银屑病的整体治疗研究. [J]解放军医学杂志.2009,3.34(3):246.
[78]黄畋,张淑芝,孙令.心得安涂药造成豚鼠耳部银屑病样病理变化[J].中华皮肤科杂志,1991,24(2):96-97.
[79]高学敏.中药学[M].北京:中国中医药出版社,2003.172.
[80]高学敏.中药学[M].北京:中国中医药出版社,2003.116.
[81]高学敏.中药学[M].北京:中国中医药出版社,2003.124.
[82]高学敏.中药学[M].北京:中国中医药出版社,2003.110.
[83]江苏新医学院.中药大词典[M].上海:上海人民出版社,1977.2434.
[84] Kalashnikova N A,Gerashchenko G I.Antiphlogistic activity of several flavonoids [J].Aktual Vopr Farm,1974(2):352.
[85]高学敏.中药学[M].北京:中国中医药出版社,2003.167.
[86]吴焕.活血化瘀药的活性成分和药理研究进展(续).中草药通讯,1979, (10):51.
[87]高学敏.中药学[M].北京:中国中医药出版社,2003.377.
[88]高学敏.中药学[M].北京:中国中医药出版社,2003.385.
[89]高学敏.中药学[M].北京:中国中医药出版社,2003.343.
[90]高学敏.中药学[M].北京:中国中医药出版社,2003.248.